Physician profile
Angela W Mitchell
NPI 1023174604
$5,067.41
in general payments reported to CMS, 2019-2025
22 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $1,123 · 2023: $1,835 · 2024: $608 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,186.52 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,052.23 | 2021-2024 | |
| Novo Nordisk INC | $488.22 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $382.85 | 2024-2025 | Auvelity |
| Esperion Therapeutics, INC. | $342.24 | 2021-2022 | |
| Lilly USA, LLC | $274.51 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $258.59 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $230.83 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Almatica Pharma LLC | $156.39 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Organogenesis INC. | $146.05 | 2023 | Puraply |
| Sanofi-Aventis U.S. LLC | $113.93 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.58 | 2023 | Jardiance, Synjardy |
| Pfizer INC. | $74.40 | 2021-2024 | |
| Acerus Pharmaceuticals Corporation | $54.30 | 2022 | |
| Tolmar, INC. | $43.68 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.17 | 2021-2025 | Spravato |
| Abbott Laboratories | $23.78 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $23.05 | 2024 | Abilify Asimtufii |
| Antares Pharma, INC. | $19.31 | 2024 | Xyosted |
| Shield Therapeutics INC | $19.02 | 2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $15.49 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.